STAT+: Civica Rx begins selling its first generic drug as it tries to overhaul the pharmaceutical supply chain

In the latest bid to address high prescription drug costs, a nonprofit plans to sell a cheaper generic version of an expensive cancer medicine in the U.S.

Civica Rx, which was formed four years ago, is working with a generic manufacturer to supply pharmacies with the abiraterone prostate cancer treatment for $160 for a month’s supply. And the nonprofit is suggesting pharmacies sell the medicine to consumers for $171, which is considerably less than what most consumers currently pay for brand-name version, Zytiga.

Continue to STAT+ to read the full story…